Logo image of OPNT

OPIANT PHARMACEUTICALS INC (OPNT) Stock Price, Quote, News and Overview

NASDAQ:OPNT - Nasdaq - US6837501039 - Common Stock - Currency: USD

20.65  -0.12 (-0.58%)

After market: 20.75 +0.1 (+0.48%)

OPNT Quote, Performance and Key Statistics

OPIANT PHARMACEUTICALS INC

NASDAQ:OPNT (3/1/2023, 8:00:03 PM)

After market: 20.75 +0.1 (+0.48%)

20.65

-0.12 (-0.58%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High27.36
52 Week Low7.34
Market Cap108.80M
Shares5.27M
Float4.70M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO09-18 2017-09-18


OPNT short term performance overview.The bars show the price performance of OPNT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80

OPNT long term performance overview.The bars show the price performance of OPNT in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20

The current stock price of OPNT is 20.65 USD. In the past month the price increased by 2.33%. In the past year, price decreased by -22.31%.

OPIANT PHARMACEUTICALS INC / OPNT Daily stock chart

OPNT Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.21 829.40B
NVO NOVO-NORDISK A/S-SPONS ADR 27.44 390.99B
JNJ JOHNSON & JOHNSON 16.25 390.76B
AZN ASTRAZENECA PLC-SPONS ADR 20.56 230.17B
MRK MERCK & CO. INC. 11.71 226.40B
NVS NOVARTIS AG-SPONSORED ADR 13.77 215.98B
PFE PFIZER INC 8.46 149.04B
SNY SANOFI-ADR 13.58 136.54B
BMY BRISTOL-MYERS SQUIBB CO 48.97 113.23B
GSK GSK PLC-SPON ADR 7.78 74.77B
ZTS ZOETIS INC 27.1 72.39B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.95 44.58B

About OPNT

Company Profile

OPNT logo image Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The company is headquartered in Santa Monica, California and currently employs 37 full-time employees. The company went IPO on 2017-09-18. The firm developed NARCAN (naloxone hydrochloride) Nasal Spray (NARCAN), a treatment to reverse opioid overdose. The firm's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), and Acute Cannabinoid Overdose (ACO). The firm is also pursuing other treatment opportunities within the addiction and drug overdose field. Its lead development product is OPNT003 a nasal nalmefene for the treatment of opioid overdose.

Company Info

OPIANT PHARMACEUTICALS INC

233 Wilshire Blvd, Suite 400

Santa Monica CALIFORNIA 90401 US

CEO: Roger Crystal

Employees: 37

Company Website: https://www.opiant.com/

Phone: 13105985410.0

OPIANT PHARMACEUTICALS INC / OPNT FAQ

What is the stock price of OPIANT PHARMACEUTICALS INC today?

The current stock price of OPNT is 20.65 USD. The price decreased by -0.58% in the last trading session.


What is the ticker symbol for OPIANT PHARMACEUTICALS INC stock?

The exchange symbol of OPIANT PHARMACEUTICALS INC is OPNT and it is listed on the Nasdaq exchange.


On which exchange is OPNT stock listed?

OPNT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for OPIANT PHARMACEUTICALS INC stock?

7 analysts have analysed OPNT and the average price target is 21.42 USD. This implies a price increase of 3.73% is expected in the next year compared to the current price of 20.65. Check the OPIANT PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is OPIANT PHARMACEUTICALS INC worth?

OPIANT PHARMACEUTICALS INC (OPNT) has a market capitalization of 108.80M USD. This makes OPNT a Micro Cap stock.


How many employees does OPIANT PHARMACEUTICALS INC have?

OPIANT PHARMACEUTICALS INC (OPNT) currently has 37 employees.


What are the support and resistance levels for OPIANT PHARMACEUTICALS INC (OPNT) stock?

OPIANT PHARMACEUTICALS INC (OPNT) has a support level at 20.53 and a resistance level at 20.78. Check the full technical report for a detailed analysis of OPNT support and resistance levels.


Is OPIANT PHARMACEUTICALS INC (OPNT) expected to grow?

The Revenue of OPIANT PHARMACEUTICALS INC (OPNT) is expected to decline by -80.95% in the next year. Check the estimates tab for more information on the OPNT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy OPIANT PHARMACEUTICALS INC (OPNT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does OPIANT PHARMACEUTICALS INC (OPNT) stock pay dividends?

OPNT does not pay a dividend.


What is the Price/Earnings (PE) ratio of OPIANT PHARMACEUTICALS INC (OPNT)?

OPIANT PHARMACEUTICALS INC (OPNT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.55).


OPNT Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to OPNT. When comparing the yearly performance of all stocks, OPNT is a bad performer in the overall market: 63.88% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

OPNT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to OPNT. OPNT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OPNT Financial Highlights

Over the last trailing twelve months OPNT reported a non-GAAP Earnings per Share(EPS) of -6.55. The EPS decreased by -13200% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity 0.6
Chartmill High Growth Momentum
EPS Q2Q%-442.86%
Sales Q2Q%-98.94%
EPS 1Y (TTM)-13200%
Revenue 1Y (TTM)-49.13%

OPNT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 46% to OPNT. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of -2455.56% and a revenue growth -80.95% for OPNT


Ownership
Inst OwnersN/A
Ins Owners2.97%
Short Float %N/A
Short RatioN/A
Analysts
Analysts45.71
Price Target21.42 (3.73%)
EPS Next Y-2455.56%
Revenue Next Year-80.95%